The historical rank and industry rank for Xenetic Biosciences's FCF Margin % or its related term are showing as below:
XBIO'
s FCF Margin % Range Over the Past 10 Years
Min: -37641.18 Med: -301.52 Max: 19.58
Current: -170.59
During the past 13 years, the highest FCF Margin % of Xenetic Biosciences was 19.58%. The lowest was -37641.18%. And the median was -301.52%.
XBIO's FCF Margin % is ranked worse than 52.44% of 1045
companies
in the Biotechnology industry
Industry Median: -143.92
vs XBIO: -170.59
Xenetic Biosciences FCF Margin % Historical Data
The historical data trend for Xenetic Biosciences's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Xenetic Biosciences's FCF Margin %
For the Biotechnology subindustry, Xenetic Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenetic Biosciences's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Xenetic Biosciences's FCF Margin % falls into.
Xenetic Biosciences FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
Xenetic Biosciences's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenetic Biosciences FCF Margin % Related Terms
Thank you for viewing the detailed overview of Xenetic Biosciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Xenetic Biosciences (Xenetic Biosciences) Business Description
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XBIO has been successfully added to your 